Commentary: Treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-virals

Wong V.W.-S.CHUN-JEN LIU2022-01-242022-01-2420140269-2813https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901376309&doi=10.1111%2fapt.12745&partnerID=40&md5=dc6e909c00c5917e14627ff9e2012d32https://scholars.lib.ntu.edu.tw/handle/123456789/593123[SDGs]SDG1[SDGs]SDG3boceprevir; peginterferon; ribavirin; telaprevir; virus RNA; antiviral therapy; decompensated liver cirrhosis; drug efficacy; drug tolerability; hepatitis C; Hepatitis C virus genotype 1; hospitalization; human; liver cirrhosis; note; priority journal; reinfection; treatment indication; treatment outcome; treatment response; virus replication; Antiviral Agents; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; MaleCommentary: Treatment of hepatitis C-related cirrhosis in the era of direct-acting anti-viralsnote10.1111/apt.12745248491492-s2.0-84901376309